ICOS/Biogen to develop oral therapeutics
US firms ICOS Corp and Biogen have agreed to collaborate worldwide onthe development and commercialization of orally-active, small molecule leukocyte function-associated antigen-1 antagonists (including ICOS' IC747, currently in a Phase I clinical trial) as oral therapeutics for the treatment of inflammatory conditions.
Under the terms of the deal, ICOS and Biogen will cross-license their LFA-1 antagonist technology and patents, including IC747, with the two companies sharing costs for ongoing development activities, including co-promotion and profits equally. ICOS will receive an $8 million up-front payment and other success-based milestones from Biogen. Additionally, Biogen will provide ICOS with a loan (which may be forgiven upon meeting certain milestones) towards its development costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze